αααααβααΎα49BA β’ FRA
add
BeOne Medicines AG
308.00β¬
18 αα·α
ααα·ααΆ, 11:46:06 PM ααααβααα +1 · EUR · FRA · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
302.00β¬
α
αααααααααααα
302.00β¬ - 308.00β¬
α
ααααααα½αααααΆαα
α»αααααα
166.00β¬ - 322.00β¬
ααΎαβαα»αβααΈααααΆα
344.95Β αααΈααΆα HKD
ααα ααα½αααΌαααααα
5.00
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | 1.41Β αααΈααΆα | 41.00% |
α
αααΆαααααα·ααααα·ααΆα | 1.05Β αααΈααΆα | 10.64% |
α
αααΌααα»ααα | 124.84Β ααΆα | 202.88% |
ααααΆααα
αααααα»ααα | 8.84 | 172.94% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 1.09 | 267.89% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 198.86Β ααΆα | 496.46% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 15.17% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 4.04Β αααΈααΆα | 48.74% |
ααααααααα»α | 7.63Β αααΈααΆα | 31.04% |
ααΆαααα½ααα»αααααΌαααα»α | 3.50Β αααΈααΆα | 47.29% |
ααΌαβααααα»α | 4.13Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 110.66Β ααΆα | β |
ααααααααααΉαααααα
| 8.09 | β |
ααα
ααααααΎαααααα | 5.85% | β |
ααα
ααααααΎααΎααα»α | 8.20% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | αααααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | 124.84Β ααΆα | 202.88% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 402.55Β ααΆα | 113.70% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -49.27Β ααΆα | 63.20% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | 961.27Β ααΆα | 7,491.79% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 1.32Β αααΈααΆα | 1,286.91% |
ααα αΌαααΆα
αααααΆααααααα | 306.27Β ααΆα | 120.68% |
α’αααΈ
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
ααΆααααααΎαα‘αΎα
28 αα»ααΆ 2010
αααααβαααααΆα
αα»ααααα·α
11,000
